Covid-19 roundup: AstraZeneca's Farxiga fails PhIII test; Supply deal for Eli Lilly's solo bamlanivimab officially canceled
Around the same time AstraZeneca struck up a vaccine partnership with Oxford last April, the pharma giant also put together a game plan to develop …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
